BPH treatment device market seen reaching $1.86 billion by 2030

The global market for benign prostatic hyperplasia treatment devices and equipment is projected to grow from $1.34 billion in 2025 to $1.86 billion by 2030, driven by aging men, more minimally invasive care, and wider use of laser and implant-based therapies. North America led the market in 2025, while prostate cancer diagnoses continue to push more men into prostate health evaluation.

Why it matters: - The BPH treatment devices and equipment market is moving toward broader use of minimally invasive urology tools. - The market is projected to reach $1.86 billion by 2030, signaling sustained demand for devices that help treat urinary obstruction linked to enlarged prostates. - Aging populations and shorter hospital stays are pushing care toward outpatient and lower-burden treatment options.

What happened: - The Business Research Company projected the global BPH treatment devices and equipment market will rise from $1.34 billion in 2025 to $1.43 billion in 2026. - The company said the market will grow at a 6.3% CAGR from 2025 to 2026. - The market is forecast to reach $1.86 billion by 2030, with a 6.9% CAGR from 2026 to 2030. - North America was the largest regional market in 2025. - Western Europe ranked second in 2025.

The details: - Benign prostatic hyperplasia, also called benign prostatic hypertrophy, is an enlargement of the prostate gland. - The condition can block the urethra and make urination difficult. - Historical market growth has been supported by rising BPH incidence, greater awareness of urological disorders, wider use of transurethral procedures, expansion of hospital urology units, and better endoscopic surgical tools. - Future growth is expected to come from an aging male population, more demand for minimally invasive treatments, growth in outpatient urology clinics, broader adoption of laser and implant-based therapies, and efforts to reduce hospital stays. - The market report covers Asia-Pacific, Southeast Asia, Eastern Europe, South America, the Middle East, and Africa in addition to North America and Western Europe. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company offered a free sample report and a full market report through its website. - More information - The full report

Between the lines: - Rising prostate cancer cases are adding to prostate-health screening and evaluation, which can increase diagnosis and management of BPH. - ASCO reported in February 2023 that about 288,300 men in the U.S. were living with prostate cancer in 2023, along with 268,490 new diagnoses and 34,500 deaths in 2022. - The forecast suggests suppliers of laser, implant-based and endoscopic systems may benefit as providers shift toward less invasive care.

What's next: - The market will likely keep expanding as outpatient urology clinics grow and hospitals look to shorten recovery times. - Regional competition will continue to be led by North America, with Europe and Asia-Pacific remaining important markets to watch. - The Business Research Company is pitching expanded 2026 report tools and forecasting resources to buyers seeking market planning data. - The company's announcement